Bosh sahifaNOVO-B • CPH
add
Novo Nordisk A/S
Yopilish kursi
630,00 kr
Kunlik diapazon
626,00 kr - 640,70 kr
Yillik diapazon
526,00 kr - 1 033,20 kr
Bozor kapitalizatsiyasi
2,14 trln DKK
Oʻrtacha hajm
4,12 mln
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
CPH
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(DKK) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Daromad | 71,31 mlrd | 21,42% |
Joriy xarajat | 26,18 mlrd | 18,44% |
Sof foyda | 27,30 mlrd | 21,46% |
Sof foyda marjasi | 38,28 | 0,03% |
Har bir ulushga tushum | 6,12 | 22,40% |
EBITDA | 35,97 mlrd | 22,20% |
Amaldagi soliq stavkasi | 20,60% | — |
Balans
Jami aktivlari
Jami passivlari
(DKK) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 74,88 mlrd | 57,33% |
Jami aktivlari | 397,44 mlrd | 32,44% |
Jami passivlari | 276,92 mlrd | 33,71% |
Umumiy kapital | 120,52 mlrd | — |
Tarqatilgan aksiyalar | 4,45 mlrd | — |
Narxi/balansdagi bahosi | 23,27 | — |
Aktivlardan daromad | 22,05% | — |
Kapitaldan daromad | 48,72% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(DKK) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Sof foyda | 27,30 mlrd | 21,46% |
Operatsiyalardan naqd pul | 43,85 mlrd | 7,04% |
Sarmoyadan naqd pul | -20,90 mlrd | -57,85% |
Moliyadan naqd pul | -18,40 mlrd | 7,22% |
Naqd pulning sof oʻzgarishi | 4,20 mlrd | -49,49% |
Boʻsh pul | 25,22 mlrd | -14,56% |
Haqida
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark with production facilities in nine countries and affiliates or offices in five countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28% of its shares and a majority of its voting shares.
Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes care medications and devices. Its main product is the drug semaglutide, used to treat diabetes under the brand names Ozempic and Rybelsus and obesity under the brand name Wegovy. Novo Nordisk is also involved with hemostasis management, growth hormone therapy, and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.
Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. The Novo Nordisk logo is the Apis bull, one of the sacred animals of ancient Egypt, denoted by the hieroglyph 𓃒. Wikipedia
Tashkil etilgan
21-dek, 1923
Sayt
Xodimlar soni
71 880